PDGFRA and hypereosinophilic syndrome: In a multicenter study of 188 subjects with HES, 179 of whom had the FLP1L1-PDGFRA mutation and were treated with CS, 65% were non-responders.[20,21] Among the responders, there are no clear evidence-based recommendations that can be given.